Kandzi, J. D., Englisch, A., Böer, B., Hahn, M., Wallwiener, M., Volmer, L., . . . Engler, T. (2025). Reconciling sentinel node omission with CDK4/6 inhibitor eligibility in HR+/HER2- early breast cancer: A real-world cohort analysis. Clinical breast cancer. https://doi.org/10.1016/j.clbc.2025.10.003
Chicago-Zitierstil (17. Ausg.)Kandzi, Jannik Daniel, Alexander Englisch, Bettina Böer, Markus Hahn, Markus Wallwiener, Léa Volmer, Sara Brucker, Andreas Hartkopf, und Tobias Engler. "Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-world Cohort Analysis." Clinical Breast Cancer 2025. https://doi.org/10.1016/j.clbc.2025.10.003.
MLA-Zitierstil (9. Ausg.)Kandzi, Jannik Daniel, et al. "Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-world Cohort Analysis." Clinical Breast Cancer, 2025, https://doi.org/10.1016/j.clbc.2025.10.003.